Featured Story

  • Sequenom scores a blow against Illumina in prenatal Dx patent fight

    Sequenom scored against Illumina's Verinata Health in a ruling at the U.S. Patent and Trademark Office involving noninvasive prenatal genetic diagnostic tech. Wasting no time, executives plan to use that decision as a weapon in an ongoing legal battle between the two California companies.

MDxHealth broadens reach of prostate cancer Dx with new U.S. PPO deal

MDxHealth will ally with a Texas-based provider network in a deal that will greatly expand the reach of its signature prostate cancer molecular diagnostic test to millions of additional patients.

KineMed, with IPO in sight, joins global diabetes biomarker research project

KineMed, a California biomarker test developer with IPO plans, is joining a consortium that will create a standard mouse model focused on diagnosis and tracking of early-onset diabetes.

UW-Madison team concocts asthma blood Dx that could work before symptoms appear

A rapid diagnostic blood test for asthma--one that works even in mild cases, before symptoms appear--showed some promise in new research. What's more, the handheld device developed for the diagnostic process would cost little to use, they said.

Cepheid's 2014 Q1 produced Dx sales hikes but also more losses

Cepheid booked much higher sales during its fiscal 2014 first quarter and successfully launched new HPV and norovirus molecular diagnostic tests outside of the U.S. But the California company faced a net loss as it dealt with higher overall costs and continued to work through restructuring.

Investors initially respond well to Abbott's diagnostics gains

Investors drove Abbott Laboratories' stock higher the week before Easter, heartened by diagnostics sales that keep climbing even as its medical devices arm faced continued challenges.